Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

被引：137
作者：
Kappel, Ben A. [1 ]
Lehrke, Michael [1 ]
Schutt, Katharina [1 ]
Artati, Anna [2 ]
Adamski, Jerzy [2 ,3 ,4 ]
Lebherz, Corinna [1 ]
Marx, Nikolaus [1 ]
机构：
[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany
[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Muchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany
[3] Tech Univ Munich, Life & Food Sci Ctr Weihenstephan, Inst Expt Genet, Freising Weihenstephan, Germany
[4] German Ctr Diabet Res, Neuherberg, Germany
来源：
CIRCULATION | 2017年 / 136卷 / 10期
关键词：
branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; SGTL2; inhibitors; type 2 diabetes mellitus; OUTCOMES;
D O I：
10.1161/CIRCULATIONAHA.117.029166
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：969 / 972
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
    Lingvay, Ildiko
    Greenberg, Michelle
    Gallo, Silvina
    Shi, Harry
    Liu, Jie
    Gantz, Ira
    DIABETES OBESITY & METABOLISM, 2021, 23 (07) : 1640 - 1651
  • [22] The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus
    Shetty, Sharash
    Stafkey-Mailey, Dana
    Yue, Binglin
    Coutinho, Anna D.
    Wang, Weijia
    Del Parigi, Angelo
    Sander, Stephen D.
    Coleman, Craig, I
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1081 - 1087
  • [23] Effect of Add-On Therapy of Dapagliflozin and Empagliflozin on Adipokines in Type 2 Diabetes Mellitus
    Shaheer, Abid
    Kumar, Ashok
    Menon, Palat
    Jallo, Mahir
    Basha, Shaikh
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2021, 11 (3-4) : 83 - 90
  • [24] Options for empagliflozin in combination therapy in type 2 diabetes mellitus
    Hershon, Kenneth S.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 155 - 172
  • [25] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
    Lai, Lee-Lee
    Vethakkan, Shireene Ratna
    Nik Mustapha, Nik Raihan
    Mahadeva, Sanjiv
    Chan, Wah-Kheong
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (02) : 623 - 631
  • [26] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    John E. Anderson
    Eugene E. Wright
    Charles F. Shaefer
    Diabetes Therapy, 2017, 8 : 33 - 53
  • [27] Epidemiological Evidence of Type 2 Diabetes Mellitus, Metabolic Syndrome, and Cardiovascular Disease in Japan
    Saito, Isao
    CIRCULATION JOURNAL, 2012, 76 (05) : 1066 - 1073
  • [28] The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
    Pokharel, Arbinda
    Sudhamshu, K. C.
    Thapa, Pukar
    Karki, Niyanta
    Shrestha, Rupesh
    Jaishi, Bikash
    Paudel, Mukesh S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
  • [29] EMPAGLIFLOZIN: A NEW TREATMENT OPTION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Dailey, G. E.
    DRUGS OF TODAY, 2015, 51 (09) : 519 - 535
  • [30] Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk
    Stalenhoef, A. F. H.
    Davidson, M. H.
    Robinson, J. G.
    Burgess, T.
    Duttlinger-Maddux, R.
    Kallend, D.
    Goldberg, A. C.
    Bays, H.
    DIABETES OBESITY & METABOLISM, 2012, 14 (01) : 30 - 39
12345